Advaxis, Inc. (NASDAQ:ADXS) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Tuesday.
Several other equities research analysts also recently weighed in on the company. BidaskClub downgraded Advaxis from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Cantor Fitzgerald set a $19.00 price target on Advaxis and gave the stock a “buy” rating in a report on Thursday, July 6th. Finally, HC Wainwright set a $23.00 price target on Advaxis and gave the stock a “buy” rating in a report on Wednesday, June 14th. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $22.00.
Shares of Advaxis (ADXS) traded down 2.93% during trading on Tuesday, reaching $6.30. 359,138 shares of the company were exchanged. The firm’s market capitalization is $254.91 million. The firm’s 50 day moving average is $6.60 and its 200 day moving average is $7.96. Advaxis has a 1-year low of $5.70 and a 1-year high of $16.30.
WARNING: “ValuEngine Downgrades Advaxis, Inc. (ADXS) to Strong Sell” was first posted by BBNS and is the property of of BBNS. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://baseballnewssource.com/markets/valuengine-downgrades-advaxis-inc-adxs-to-strong-sell/1410168.html.
Several large investors have recently added to or reduced their stakes in ADXS. Stevens Capital Management LP purchased a new stake in Advaxis during the first quarter worth approximately $105,000. Cutler Capital Management LLC purchased a new stake in Advaxis during the second quarter worth approximately $130,000. Stonebridge Capital Management Inc. purchased a new stake in Advaxis during the second quarter worth approximately $146,000. American International Group Inc. increased its stake in Advaxis by 7.6% in the first quarter. American International Group Inc. now owns 20,666 shares of the biotechnology company’s stock worth $169,000 after buying an additional 1,459 shares during the period. Finally, PNC Financial Services Group Inc. increased its stake in Advaxis by 4.8% in the first quarter. PNC Financial Services Group Inc. now owns 22,000 shares of the biotechnology company’s stock worth $180,000 after buying an additional 1,000 shares during the period. 54.95% of the stock is owned by hedge funds and other institutional investors.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with our FREE daily email newsletter.